FDA OKs Subcutaneous Therapy for CIDP FDA OKs Subcutaneous Therapy for CIDP

HyQvia, which combines immunoglobulin with hyaluronidase, is administered subcutaneously by a healthcare professional or the patient or caregiver, after appropriate training.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Source Type: news